NSAID Risk Matrix • ACG/AGA Guidelines
Complication Risk Factors
Apply patient risk factors to visualize the ACG/AGA NSAID safety profile.
Guidelines & Evidence
Verified
Last Review: 2026-07-17
When to Use
When to Use
Selecting the safest NSAID or COX-2 inhibitor regimen for patients requiring long-term anti-inflammatory therapy
To identify patients who require co-therapy with a Proton Pump Inhibitor (PPI) or Misoprostol
Evaluating the risk of upper GI bleeding, perforation, or obstruction (PUPO)
The "GI vs. CV" Balance
Clinical decision-making for NSAIDs must balance GI risk against Cardiovascular (CV) risk. A patient with high GI risk but high CV risk should generally avoid both traditional NSAIDs and COX-2 inhibitors.
How it Works
High-Risk Features
History of prior complicated ulcer (Perforation/Obstruction/Bleeding).
Age > 65 years.
Concomitant Use of: anticoagulants (warfarin/DOAC), anti-platelets (aspirin/clopidogrel), or oral corticosteroids.
Multiple NSAID use (including low-dose aspirin).
High-dose NSAID therapy.
Concomitant H. pylori infection.
Risk Stratification (ACG 2009)
| High Risk | Prior complicated ulcer OR > 2 risk factors |
| Moderate Risk | 1–2 risk factors |
| Low Risk | No risk factors |
Clinical Pearls
COX-2 Inhibitors and the Gut
Celecoxib (COX-2 selective) significantly reduces the risk of macroscopic GI ulcers compared to traditional NSAIDs (like naproxen or ibuprofen). However, when Celecoxib is combined with low-dose Aspirin, its GI safety advantage is nearly completely lost.
Naproxen — The Cardiovascular Paradox
Naproxen is generally considered the "safest" NSAID for patients with high cardiovascular risk (lowest risk of MACE), but it is associated with a higher risk of GI bleeding compared to Ibuprofen or Celecoxib. For these patients, Naproxen + PPI is often the preferred strategy.
Clinical Pearls
Co-prescription of a PPI reduces the risk of symptomatic NSAID-ulcers by > 70%
Misoprostol is also highly effective but limited by GI side effects (dose-dependent diarrhea)
The risk of a GI event is highest during the first month of NSAID initiation
Next Steps
Management Recommendations (ACG)
| Low Risk | Traditional NSAID at lowest effective dose |
| Moderate Risk | NSAID + PPI (or Misoprostol) OR COX-2 inhibitor alone |
| High Risk | COX-2 inhibitor + PPI OR alternative therapy (e.g., Acetaminophen/Opioids) |
The Evidence
ACG Clinical Guideline
Guidelines for prevention of NSAID-related ulcer complications.
Lanza FL et al. • American Journal of Gastroenterology. 2009;104(3):728-38. The definitive evidence-based roadmap.
View Source• . ;
PRECISION Trial (CV vs GI)
Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis.
Nissen SE et al. • N Engl J Med. 2016;375(26):2519-29. Large RCT clarifying long-term risk profiles.
View SourceOrigins & History
The ACG Expert Panel
The American College of Gastroenterology convened this panel to address the "hidden epidemic" of NSAID gastropathy, which was responsible for over 100,000 hospitalizations in the US annually before the widespread use of PPIs.
Last Comprehensive Review: 2026-07-17